Santarus submits ulcerative colitis NDA, inks cholesterol drug deal with Shore
This article was originally published in Scrip
Executive Summary
The day after submitting a new drug application to the US FDA for Uceris (budesonide) as a treatment to induce remission of mild to moderate active ulcerative colitis, San Diego-based Santarus revealed after the market closed on 21 December that it had entered into an exclusive license agreement commercialize with Shore Therapeutics' cholesterol drug Fenoglide (fenofibrate).